FDA consumer warning
This article was originally published in The Tan Sheet
Executive Summary
The dietary supplements Emagrece Sim and Herbathin should not be used and should be returned to suppliers because they "may contain several active ingredients, including controlled substances, found in prescription drugs that could lead to serious side effects or injury," the agency announces Jan. 13. FDA has issued an import alert to prevent importation of the products, which are made in Brazil by the firms Fitoterapicos and Phytotherm Sim. The products contain fluoxetine HCl (Prozac) and chlordiazepoxide HCl (Librium), which are used to relieve anxiety, according to FDA. They also were found to contain Fenproporex, a stimulant that is "not approved for marketing in the U.S." and is converted in the body to amphetamine. The supplements are sold on the Internet, and FDA is "aware of commercial imports of these products and individuals importing them for personal use"...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.